OBJECTIVE: Using data from a randomized trial of @entity18651 , we assessed the differences between Canada and the United States in the use of medical resources and outcomes in the treatment of @entity510 during the first 90 days after admission to the hospital. METHODS: Of the 877 @entity1 for whom economic data were available, 194 were enrolled in Canada and 683 were enrolled in the United States. The differences between the countries in @entity1 characteristics, use of medical resources, and outcomes were analyzed by comparing means and the 95% confidence intervals (CIs) around the differences in means. These differences also were predicted with use of multivariable regression analysis. RESULTS: The average hospital stay was 4.2 days longer (95% CI, 1.3 to 7.1 days) in Canada, but most of the extra stay was among @entity1 admitted to the study in poor @entity16 . In general, however, hospital stays in Canada were substantially less intensive. @entity1 treated in Canada spent 3.7 fewer days (95% CI, 1.2 to 6.1 days) in nursing homes and rehabilitation centers than did @entity1 in the United States. No statistically significant differences were seen for Glasgow Outcome Scale score, death, and occurrence of @entity2553 . CONCLUSIONS: For @entity1 admitted to the study in good @entity16 , the apparent difference in length of stay between Canada and the United States was caused by a shift in the sites of formal care rather than to the length of this care. For those admitted in poor @entity16 , both the length and sites of care differed between the two countries. No significant difference in outcomes appeared to justify these differences in the use of medical resources.

Comparison of the use of medical resources and outcomes in the treatment of XXXX between Canada and the United States.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity510 :: ('MESH:D013345', 'Disease') :: ['aneurysmal subarachnoid hemorrhage'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological condition'] @entity18651 :: ('MESH:C053355', 'Chemical') :: ['tirilazad mesylate'] @entity2553 :: ('MESH:D020301', 'Disease') :: ['vasospasm']
@entity510 :: (MESH:D013345,Disease) :: ['aneurysmal subarachnoid hemorrhage']
